Tudorza Pressair (Aclidinium Bromide) Patent Expiration, LOE Window & CMS Spending

Tudorza Pressair (Aclidinium Bromide) by Azurity: FDA Orange Book LOE 2029-03-13, 0 AB generics, $7.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN202450 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2029-03-13
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$7.0M
2024 Medicare Part D Spend$5.1M
2024 Medicaid Spend$1.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel